» Articles » PMID: 37779622

Transgender Individuals Are at Higher Risk for Suicidal Ideation and Preparation Than Cisgender Individuals in Substance Use Treatment

Overview
Specialty Psychiatry
Date 2023 Oct 2
PMID 37779622
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: This study describes the differences and similarities in mental health, substance use, and substance use treatment outcomes between people presenting for SUD treatment who identified as transgender and those who identified as cisgender men or women.

Methods: We compared 64 individuals who self-identified as transgender and presented for SUD treatment to samples of cisgender men and women (separately) matched based on propensity scores which were created based on sociodemographic factors known to influence both the nature of substance use and patterns of treatment engagement including age, education, race, stable housing, and employment status. Comparisons were made using χ tests and tests in over 150 variables collected at treatment intake regarding physical and mental health, substance use patterns, events that led to treatment, reasons for seeking treatment, and treatment outcomes.

Results: The transgender sample endorsed six of the seven suicide-related items more often than at least one of the cisgender-matched samples. Furthermore, the transgender sample remained in treatment significantly longer (M = 32.3, SD = 22.2) than the cisgender male sample (M = 19.5, SD = 26.1, t = 2.17, = 0.03).

Discussion: This study is a first step into understanding gender minority population experiences during SUD treatment. While there was no significant difference between the cisgender and transgender samples on most variables, there was an elevated prevalence of suicidal ideation and behaviors in the transgender sample, which warrants further investigation.

Citing Articles

Analysis of single nucleotide polymorphisms of the metabotropic glutamate receptors in a transgender population.

Fernandez R, Ramirez K, Lorente-Bermudez R, Gomez-Gil E, Mora M, Guillamon A Front Endocrinol (Lausanne). 2024; 15:1382861.

PMID: 38919484 PMC: 11196815. DOI: 10.3389/fendo.2024.1382861.

References
1.
Glick J, Theall K, Andrinopoulos K, Kendall C . For data's sake: dilemmas in the measurement of gender minorities. Cult Health Sex. 2018; 20(12):1362-1377. PMC: 6526522. DOI: 10.1080/13691058.2018.1437220. View

2.
Some N, Shokoohi M, Shield K, Wells S, Hamilton H, Elton-Marshall T . Alcohol and cannabis use during the COVID-19 pandemic among transgender, gender-diverse, and cisgender adults in Canada. BMC Public Health. 2022; 22(1):452. PMC: 8899793. DOI: 10.1186/s12889-022-12779-9. View

3.
Meyer T, Crist N, La Rosa N, Ye B, Soares J, Bauer I . Are existing self-ratings of acute manic symptoms in adults reliable and valid?-A systematic review. Bipolar Disord. 2020; 22(6):558-568. DOI: 10.1111/bdi.12906. View

4.
Gunn C, Pankowska M, Harris M, Helsing E, Battaglia T, Bagley S . The representation of females in clinical trials for substance use disorder conducted in the United States (2010-19). Addiction. 2022; 117(10):2583-2590. PMC: 10062729. DOI: 10.1111/add.15842. View

5.
Lombardi E, Banik S . The Utility of the Two-Step Gender Measure Within Trans and Cis Populations. Sex Res Social Policy. 2021; 13(3):288-296. PMC: 8699571. DOI: 10.1007/s13178-016-0220-6. View